We develop genetic tests to personalize medicine. Starting with hypertension. Getting patients better faster with less cost. Supported by clinical evidence.
#renaldenervation holds tremendous promise as a treatment for #hypertension (#highbloodpressure) — but its adoption has been limited by one challenge: it doesn’t work for everyone. Some even have an increase in BP after #RDN. @geneticure has solved this.
https://t.co/9ZPcCge07b
Thank you @thelancet for publishing our letter on 3yr #renaldenervation data. Reference table S3 (appendix) showing non-imputed data, to support our arguments. Only night-time SBP is sig. different between sham and #RDN (p=0.04) when data are not imputed: https://t.co/XnlXygqNnw
.@Geneticure Announces Technology to Drive an Estimated 250% Increase in Renal Denervation Adoption Using Genetic Screening to Rule Out Non-responders https://t.co/qCXGsQZnsW
#hypertension#renaldenervation
@EricTopol Intense. Certainly not a time to relax, either personally (masks and distancing) or in coming up with novel strategies for treatment. Particularly therapeutics that can have an impact in the short-term while vaccines are in development.
@JAMA_current Differences in ACE2 likely explain part of the heterogeneous response in #Covid_19. HTN, diabetes, and age are associated with more ACE2. Very likely that genetics also plays a role in who gets infected and then who is protected from cardiopulmonary dysfunction, post-infection.
"While the pandemic is bringing many things to a screeching halt, new U.S. patents are still being issued every Tuesday, adding to the tally for local inventors." via @PB_News#RochMN#innovation#patent https://t.co/rg7v5csaBV
Tonight's @RaediInfo R.A.V.E event honored @4DaughtersWine, @geneticure and Clean Plus, Inc. And, Lifetime Achievement Honoree Leigh J. Johnson, founder of @customalarm and Warrior Award Honoree @NeelaMollgaard, executive director of @LaunchMinnesota. Congrats to all.
Founded by Rochester brothers Scott and Eric Snyder in 2014, @geneticure is a precision medicine startup aimed at reducing trial and error for treatment of hypertension patients. Learn More:
https://t.co/UlzUbRi2hA
Dr. Eric Snyder from Geneticure discusses their recently presented data on a study utilizing their algorithm which can predict which hypertension drug would be most beneficial to patients based on their genetic makeup.
https://t.co/AsSrMU78Wt
#Hypertension costs $93.5 billion per year. Using our own clinical evidence, a #precisionmedicine approach using genetically guided therapy reduced total 3-yr direct costs of #highbloodpressure by 47% per simulated population: https://t.co/U96DDhTN8Z
#pharmacogenomics
“..patients who used a #hypertension (HTN) medication recommended by Geneticure was approximately 36 percent lower than in patients who were prescribed HTN medication that did not align with the Geneticure recommendation.” #pharmacogenomics https://t.co/q6h2h9jM5U
Rochester biotechnology firm, @geneticure , is gaining momentum as it moves into the individualized medicine market. RAEDI was happy to participate in their initial funding round & is looking forward to seeing them succeed! Read more about it here: https://t.co/vqCcbDtw3M